Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer : Medical Ethics Committee of Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University

High risk prostate cancer (PCa) had worse outcomes on radical treatment results, short-time oncological results, even cancer-specific survival, than those low or mediate risk PCa. Neoadjuvant treatment before radical prostatectomy had been proven to get some benefits on peri-operation results, especially on reduction of tumor volume and minimization of biochemical recurrence. This study will evaluate the efficacy and safety of androgen deprivation therapy (ADT) with abiraterone in neoadjuvant therapy for surgically resectable high-risk or very high-risk PCa..

Medienart:

Klinische Studie

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

ClinicalTrials.gov - (2022) vom: 16. Dez. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Phase: Phase 2
Prostatic Neoplasms
Recruitment Status: Active, not recruiting
Study Type: Interventional

Anmerkungen:

Source: Link to the current ClinicalTrials.gov record., First posted: April 22, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 21, 2022, Last updated: December 21, 2022

Study ID:

NCT04356430
IUNU-PC-101

Veröffentlichungen zur Studie:

fisyears:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG003367290